Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,929,738
  • Shares Outstanding, K 105,575
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • 60-Month Beta 1.00
  • Price/Sales 17.13
  • Price/Cash Flow N/A
  • Price/Book 6.95
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 33.89% ( +2.51%)
  • Historical Volatility 23.57%
  • IV Percentile 7%
  • IV Rank 5.49%
  • IV High 115.58% on 04/15/24
  • IV Low 29.15% on 08/30/24
  • Put/Call Vol Ratio 8.15
  • Today's Volume 183
  • Volume Avg (30-Day) 140
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 7,871
  • Open Int (30-Day) 6,807

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.17
  • Number of Estimates 7
  • High Estimate -0.07
  • Low Estimate -0.26
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +32.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.75 +5.18%
on 09/04/24
78.14 -3.42%
on 08/21/24
+0.64 (+0.86%)
since 08/16/24
3-Month
66.26 +13.90%
on 07/01/24
82.00 -7.96%
on 07/26/24
-0.01 (-0.01%)
since 06/18/24
52-Week
45.50 +65.87%
on 10/30/23
84.89 -11.10%
on 04/16/24
+21.56 (+39.99%)
since 09/18/23

Most Recent Stories

More News
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 74.87 (-0.32%)
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted...

ALZN : 1.7300 (+2.98%)
VNDA : 4.94 (-0.10%)
ITCI : 74.87 (-0.32%)
TEVA : 17.77 (-0.45%)
ABBV : 193.31 (-0.07%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 74.87 (-0.32%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 74.87 (-0.32%)
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024

Stocks that traded heavily or had substantial price changes on Tuesday: UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall

IP : 49.81 (+0.65%)
NTRS : 91.13 (+0.53%)
PNC : 183.45 (+1.08%)
ABX.TO : 27.35 (-1.80%)
LYV : 103.82 (+0.87%)
UNH : 581.03 (+0.53%)
ITCI : 74.87 (-0.32%)
MS : 99.78 (-0.06%)
Intra-Cellular: Q4 Earnings Snapshot

Intra-Cellular: Q4 Earnings Snapshot

ITCI : 74.87 (-0.32%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 74.87 (-0.32%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 74.87 (-0.32%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 74.87 (-0.32%)
Why Intra-Cellular Therapies Climbed Tuesday

The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.

ITCI : 74.87 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 78.11
2nd Resistance Point 77.34
1st Resistance Point 76.22
Last Price 74.87
1st Support Level 74.33
2nd Support Level 73.56
3rd Support Level 72.44

See More

52-Week High 84.89
Last Price 74.87
Fibonacci 61.8% 69.84
Fibonacci 50% 65.19
Fibonacci 38.2% 60.55
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar